A purification scheme to maximize the efficiency of the purification process and product purity while minimizing the development time for early-phase therapeutic antibodies.
Timothy Hagerty
Advertisement
Timothy Hagerty is scientist at Pfizer Global Research and Development Global Biologics, Bioprocess R&D
Articles by Timothy Hagerty
A purification scheme to maximize the efficiency of the purification process and product purity while minimizing the development time for early-phase therapeutic antibodies.
Advertisement
Latest Updated Articles
The Development and Application of a Monoclonal Antibody Purification PlatformPublished: October 2nd 2009 | Updated:
The Development and Application of a Monoclonal Antibody Purification PlatformPublished: March 2nd 2009 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
2
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
5
